US20050287630A1
(en)
*
|
1995-04-27 |
2005-12-29 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
ATE390933T1
(de)
*
|
1995-04-27 |
2008-04-15 |
Amgen Fremont Inc |
Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
|
US20050241006A1
(en)
*
|
1995-04-27 |
2005-10-27 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US20020173629A1
(en)
*
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6235883B1
(en)
*
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6358508B1
(en)
*
|
1997-06-11 |
2002-03-19 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor TR9
|
US6417168B1
(en)
*
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
US7067144B2
(en)
*
|
1998-10-20 |
2006-06-27 |
Omeros Corporation |
Compositions and methods for systemic inhibition of cartilage degradation
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
RS51309B
(sr)
*
|
1998-12-23 |
2010-12-31 |
Pfizer Inc. |
Humana monoklonalna antitela za ctla-4
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
US20040010134A1
(en)
|
2000-04-12 |
2004-01-15 |
Rosen Craig A. |
Albumin fusion proteins
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
IL146480A0
(en)
*
|
1999-05-14 |
2002-07-25 |
Imclone Systems Inc |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
CN100340575C
(zh)
|
1999-06-25 |
2007-10-03 |
杰南技术公司 |
人源化抗ErbB2抗体及其在制备药物中的应用
|
EP1792991A1
(en)
|
1999-08-24 |
2007-06-06 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
CN102206277A
(zh)
|
2000-02-10 |
2011-10-05 |
雅培制药有限公司 |
结合人白介素-18的抗体及制备和使用方法
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP2431054A3
(en)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
PT2281843T
(pt)
|
2000-06-16 |
2017-01-02 |
Human Genome Sciences Inc |
Anticorpos que se ligam imunoespecificamente a blys
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
EP1311291A4
(en)
*
|
2000-08-09 |
2007-07-25 |
Imclone Systems Inc |
TREATMENT OF HYPERPROLIFERATIVE DISEASES USING EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS
|
TWI327600B
(en)
|
2000-11-28 |
2010-07-21 |
Medimmune Llc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
EP2357187A1
(en)
|
2000-12-12 |
2011-08-17 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
EP1399483B1
(en)
|
2001-01-05 |
2010-04-14 |
Pfizer Inc. |
Antibodies to insulin-like growth factor i receptor
|
CN1564826A
(zh)
|
2001-02-09 |
2005-01-12 |
人类基因组科学公司 |
人类g蛋白趋化因子受体(ccr5)hdgnr10
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
ATE446317T1
(de)
|
2001-05-11 |
2009-11-15 |
Ludwig Inst For Cancer Res Ltd |
Spezifische bindungsproteine und ihre verwendung
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
CA2447114A1
(en)
|
2001-05-16 |
2002-11-21 |
Abgenix, Inc. |
Human antipneumococcal antibodies from non-human animals
|
MXPA03011365A
(es)
*
|
2001-06-13 |
2005-03-07 |
Genmab As |
Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr).
|
US7595378B2
(en)
*
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
AU2002357932A1
(en)
*
|
2001-12-18 |
2003-06-30 |
Whitehead Institute For Biomedical Research |
Fusion partner cells and uses thereof
|
DK1463751T3
(da)
|
2001-12-21 |
2013-08-26 |
Human Genome Sciences Inc |
Albuminfusionsproteiner.
|
US20080063639A1
(en)
*
|
2002-01-18 |
2008-03-13 |
Pierre Fabre Medicament |
Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
|
US7241444B2
(en)
*
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
US20080193445A1
(en)
*
|
2002-01-18 |
2008-08-14 |
Liliane Goetsch |
Novel anti-IGF-IR antibodies and uses thereof
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
EP1497444B1
(en)
|
2002-03-27 |
2015-11-04 |
Immunex Corporation |
Methods for increasing polypeptide production
|
PT1527100E
(pt)
|
2002-03-29 |
2009-08-25 |
Schering Corp |
Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
|
AU2003226065B2
(en)
|
2002-04-12 |
2009-02-26 |
Ludwig Institute For Cancer Research, Ltd |
Recombinant anti-interleukin-9 antibodies
|
US20050276812A1
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
US20040033543A1
(en)
*
|
2002-05-20 |
2004-02-19 |
Gisela Schwab |
Treatment of renal carcinoma using antibodies against the EGFr
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US20040022792A1
(en)
*
|
2002-06-17 |
2004-02-05 |
Ralph Klinke |
Method of stabilizing proteins at low pH
|
US20040132097A1
(en)
*
|
2002-06-19 |
2004-07-08 |
Bacus Sarah S. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
PT2263691E
(pt)
|
2002-07-15 |
2012-11-12 |
Hoffmann La Roche |
Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)
|
ATE536188T1
(de)
|
2002-08-14 |
2011-12-15 |
Macrogenics Inc |
Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
EP2298806A1
(en)
|
2002-10-16 |
2011-03-23 |
Purdue Pharma L.P. |
Antibodies that bind cell-associated CA 125/0722P and methods of use thereof
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
WO2004043405A2
(en)
*
|
2002-11-12 |
2004-05-27 |
The Brigham And Women's Hospital, Inc. |
Polysaccharide vaccine for staphylococcal infections
|
US20040147428A1
(en)
*
|
2002-11-15 |
2004-07-29 |
Pluenneke John D. |
Methods of treatment using an inhibitor of epidermal growth factor receptor
|
US20040214203A1
(en)
*
|
2002-12-12 |
2004-10-28 |
Oncotech, Inc. |
Genes related to sensitivity and resistance to chemotherapeutic drug treatment
|
WO2004058171A2
(en)
|
2002-12-20 |
2004-07-15 |
Protein Design Labs, Inc. |
Antibodies against gpr64 and uses thereof
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
EP1596813A4
(en)
*
|
2003-01-31 |
2008-02-20 |
Five Prime Therapeutics Inc |
POLYPEPTIDES EXPRESSED BY LUNGS
|
ES2457538T3
(es)
|
2003-02-20 |
2014-04-28 |
Seattle Genetics, Inc. |
Conjugados de anticuerpo anti-CD70-fármaco y su uso para el tratamiento de cánder y trastornos inmunológicos
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
PL378582A1
(pl)
|
2003-03-19 |
2006-05-02 |
Biogen Idec Ma Inc. |
Białko wiążące receptor Nogo
|
CA2521826C
(en)
|
2003-04-11 |
2013-08-06 |
Jennifer L. Reed |
Recombinant il-9 antibodies and uses thereof
|
EP1615956A1
(en)
*
|
2003-04-14 |
2006-01-18 |
Board Of Regents The University Of Texas System |
Methods for ex vivo hybridoma-free production of polyclonal and monoclonal antibodies and generation of immortalized cell populations
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
JP2007500248A
(ja)
|
2003-06-09 |
2007-01-11 |
ワクサル,サムエル |
細胞外アンタゴニストおよび細胞内アンタゴニストによる受容体チロシンキナーゼの抑制方法
|
EP1638606B1
(en)
|
2003-06-27 |
2016-01-06 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
AU2004259727A1
(en)
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of cancer and infectious diseases.
|
US20050221383A1
(en)
|
2003-08-08 |
2005-10-06 |
Choong-Chin Liew |
Osteoarthritis biomarkers and uses thereof
|
GB0321066D0
(en)
*
|
2003-09-09 |
2003-10-08 |
Pharma Mar Sau |
New antitumoral compounds
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
SG195524A1
(en)
|
2003-11-06 |
2013-12-30 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
WO2005058961A2
(en)
|
2003-12-12 |
2005-06-30 |
Amgen Inc. |
Antibodies specific for human galanin, and uses thereof
|
DK1711528T3
(da)
|
2003-12-23 |
2012-08-20 |
Genentech Inc |
Behandling af cancer med hidtil ukendte anti-il 13 monoklonale antistoffer
|
EP1759010A4
(en)
*
|
2004-01-07 |
2008-12-24 |
Bristol Myers Squibb Co |
BIOMARKERS AND METHOD FOR DETERMINING SENSITIVITY AGAINST MODULATORS OF EGF (EPIDERMAL GROWTH FACTOR) RECEPTORS
|
NL1027975C2
(nl)
|
2004-01-09 |
2005-12-23 |
Pfizer |
Antilichamen tegen MAdCAM.
|
ES2383306T3
(es)
|
2004-02-03 |
2012-06-20 |
The Regents Of The University Of Michigan |
Composiciones para el tratamiento del cáncer de mama y de páncreas
|
EP1729795B1
(en)
|
2004-02-09 |
2016-02-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
TW200533339A
(en)
*
|
2004-03-16 |
2005-10-16 |
Bristol Myers Squibb Co |
Therapeutic synergy of anti-cancer compounds
|
EP2332990A1
(en)
*
|
2004-03-19 |
2011-06-15 |
Imclone LLC |
Human anti-epidermal growth factor receptor antibody
|
US7625549B2
(en)
*
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
NZ550217A
(en)
|
2004-03-31 |
2009-11-27 |
Genentech Inc |
Humanized anti-TGF-beta antibodies
|
EP1737489B1
(en)
|
2004-04-08 |
2012-01-11 |
David B Agus |
ErbB2 antagonists for tumor pain therapy
|
SI1745075T1
(sl)
|
2004-04-21 |
2013-07-31 |
The Brigham And Women's Hospital, Inc. |
Poli-N-acetilglukozamin (PNAG/dPNAG) vezavni peptidi in postopki za njihovo uporabo
|
EP2497492B1
(en)
|
2004-06-01 |
2018-08-08 |
Icahn School of Medicine at Mount Sinai |
Genetically engineered swine influenza virus and uses thereof
|
AU2005250216B2
(en)
|
2004-06-01 |
2009-12-10 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
AU2005258335B2
(en)
|
2004-06-24 |
2011-03-17 |
Biogen Ma Inc. |
Treatment of conditions involving demyelination
|
WO2006019447A1
(en)
|
2004-07-15 |
2006-02-23 |
Xencor, Inc. |
Optimized fc variants
|
WO2006008639A1
(en)
|
2004-07-16 |
2006-01-26 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
|
US7846438B2
(en)
|
2004-08-03 |
2010-12-07 |
Biogen Idec Ma Inc. |
Methods of promoting neurite outgrowth with soluble TAJ polypeptides
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
PL1791568T3
(pl)
|
2004-08-16 |
2013-01-31 |
Quark Pharmaceuticals Inc |
Terapeutyczne zastosowania inhibitorów RTP801
|
US20060045877A1
(en)
|
2004-08-30 |
2006-03-02 |
Goldmakher Viktor S |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
US7700720B2
(en)
|
2004-09-21 |
2010-04-20 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
AU2005286607B2
(en)
|
2004-09-23 |
2011-01-27 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
EP2845865A1
(en)
|
2004-11-12 |
2015-03-11 |
Xencor Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
JP5185624B2
(ja)
|
2004-12-02 |
2013-04-17 |
ドマンティス リミテッド |
血清アルブミンおよびglp−1またはpyyを標的とする二重特異性抗体
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
KR20170134771A
(ko)
|
2005-01-21 |
2017-12-06 |
제넨테크, 인크. |
Her 항체의 고정 용량 투여법
|
CN101495498B
(zh)
|
2005-02-07 |
2013-09-18 |
基因信息公司 |
轻度骨关节炎生物标志物及其用途
|
JP5651285B2
(ja)
|
2005-02-15 |
2015-01-07 |
デューク ユニバーシティ |
抗cd19抗体および腫瘍学における使用
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
KR101253576B1
(ko)
|
2005-02-23 |
2013-04-11 |
제넨테크, 인크. |
Her 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
|
US8211430B2
(en)
|
2005-03-04 |
2012-07-03 |
Curedm Group Holdings, Llc |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
AR053553A1
(es)
|
2005-03-08 |
2007-05-09 |
Pharmacia & Upjohn Co Llc |
Composicion de anticuerpos anti molecula de adhesion celular adresina mucosa (anti-madcam)
|
US20060216288A1
(en)
*
|
2005-03-22 |
2006-09-28 |
Amgen Inc |
Combinations for the treatment of cancer
|
ES2707152T3
(es)
|
2005-04-15 |
2019-04-02 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
KR100680141B1
(ko)
*
|
2005-04-20 |
2007-02-07 |
주식회사 녹십자 |
항-egf 수용체 단일클론항체 및 이를 생산하는하이브리도마 세포주
|
EA201100642A1
(ru)
|
2005-04-25 |
2011-12-30 |
Пфайзер Инк. |
Антитела к миостатину
|
MX2007013304A
(es)
|
2005-04-26 |
2007-12-13 |
Pfizer |
Anticuerpos de p-caderina.
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
EP1885755A4
(en)
|
2005-05-05 |
2009-07-29 |
Univ Duke |
TREATMENTS OF AUTOIMMUNE DISEASES BY ANTI-CD19 ANTIBODIES
|
BRPI0611445A2
(pt)
*
|
2005-05-09 |
2010-09-08 |
Glycart Biotechnology Ag |
molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
|
AR053272A1
(es)
|
2005-05-11 |
2007-04-25 |
Hoffmann La Roche |
Determinacion de responsivos a la quimioterapia
|
CA2609667C
(en)
|
2005-05-25 |
2011-02-22 |
Curedm, Inc. |
Human proislet peptide, derivatives and analogs thereof, and methods of using same
|
GB0510790D0
(en)
|
2005-05-26 |
2005-06-29 |
Syngenta Crop Protection Ag |
Anti-CD16 binding molecules
|
AU2006261920A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Llc |
Antibody formulations having optimized aggregation and fragmentation profiles
|
ES2710289T3
(es)
|
2005-06-30 |
2019-04-24 |
Janssen Biotech Inc |
Anticuerpos anti-IL-23, composiciones, procedimientos y usos
|
MX2008000253A
(es)
|
2005-07-08 |
2008-04-02 |
Biogen Idec Inc |
Anticuerpos de sp35 y usos de los mismos.
|
MX2008001068A
(es)
*
|
2005-07-29 |
2008-03-19 |
Amgen Inc |
Formulacion que inhibe la agregacion de proteina.
|
EP2573114B1
(en)
|
2005-08-10 |
2016-03-30 |
MacroGenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP2500359A3
(en)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP2500352A1
(en)
|
2005-08-19 |
2012-09-19 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
CA2620195A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
|
MY164457A
(en)
|
2005-09-07 |
2017-12-15 |
Amgen Fremont Inc |
Human monoclonal antibodies to activin receptor-like kinase-1
|
ES2542501T3
(es)
|
2005-09-30 |
2015-08-06 |
Abbvie Deutschland Gmbh & Co Kg |
Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
|
AU2006299429B2
(en)
|
2005-10-03 |
2012-02-23 |
Xencor, Inc. |
Fc variants with optimized Fc receptor binding properties
|
TW200730825A
(en)
|
2005-10-21 |
2007-08-16 |
Genenews Inc |
Method and apparatus for correlating levels of biomarker products with disease
|
EP3299027A1
(en)
|
2005-11-04 |
2018-03-28 |
Genentech, Inc. |
Use of complement pathway inhibitors to treat ocular diseases
|
EP2510934A1
(en)
|
2005-11-04 |
2012-10-17 |
Biogen Idec MA Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
CA2628238A1
(en)
|
2005-11-07 |
2007-05-18 |
The Scripps Research Institute |
Compositions and methods for controlling tissue factor signaling specificity
|
JP2009515878A
(ja)
|
2005-11-12 |
2009-04-16 |
イーライ リリー アンド カンパニー |
抗egfr抗体
|
RU2442793C2
(ru)
|
2005-11-30 |
2012-02-20 |
Эбботт Лэборетриз |
АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
|
KR20180058863A
(ko)
|
2005-11-30 |
2018-06-01 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
|
MY147379A
(en)
|
2005-12-02 |
2012-11-30 |
Sinai School Medicine |
Chimeric viruses presenting non-native surface proteins and uses thereof
|
US20090175872A1
(en)
|
2005-12-02 |
2009-07-09 |
Biogen Idec Ma Inc. |
Treatment of Conditions Involving Demyelination
|
EP1954311A4
(en)
|
2005-12-07 |
2009-12-23 |
Medarex Inc |
CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
AR056857A1
(es)
*
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
DOP2007000015A
(es)
|
2006-01-20 |
2007-08-31 |
Quark Biotech Inc |
Usos terapéuticos de inhibidores de rtp801
|
ES2550099T3
(es)
|
2006-01-27 |
2015-11-04 |
Biogen Ma Inc. |
Antagonistas del receptor Nogo
|
MX2008015771A
(es)
|
2006-06-14 |
2009-01-27 |
Macrogenics Inc |
Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
|
WO2008019199A2
(en)
|
2006-06-26 |
2008-02-14 |
Macrogenics, Inc. |
FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
JP5622390B2
(ja)
|
2006-07-18 |
2014-11-12 |
サノフイ |
癌治療用対epha2アンタゴニスト抗体
|
SI2511301T1
(en)
|
2006-08-04 |
2018-05-31 |
MedImmune Limited, |
Human antibodies to ERBB 2
|
PT2292663E
(pt)
|
2006-08-28 |
2013-11-04 |
Kyowa Hakko Kirin Co Ltd |
Anticorpos monoclonais humanos antagonistas específicos de light humano
|
EP3339445B1
(en)
|
2006-09-08 |
2020-07-15 |
AbbVie Bahamas Ltd. |
Interleukin -13 binding proteins
|
ES2530438T3
(es)
|
2006-09-12 |
2015-03-02 |
Genentech Inc |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de KIT o KDR como marcador genético
|
MX2009003635A
(es)
*
|
2006-10-06 |
2009-04-22 |
Amgen Inc |
Formulaciones de anticuerpos estables.
|
EP2073807A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
AU2007313300A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
MX2009003982A
(es)
*
|
2006-10-20 |
2009-04-27 |
Amgen Inc |
Formulaciones de polipeptido estables.
|
US8785400B2
(en)
|
2006-11-22 |
2014-07-22 |
Curedm Group Holdings, Llc |
Methods and compositions relating to islet cell neogenesis
|
FR2909092B1
(fr)
*
|
2006-11-24 |
2012-10-19 |
Pf Medicament |
Nouveaux anticorps anti-proliferation
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2687232A1
(en)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Methods of treating systemic lupus erythematosus
|
AU2007333805B2
(en)
|
2006-12-18 |
2013-07-25 |
Genentech, Inc. |
Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
|
US8834920B2
(en)
|
2006-12-21 |
2014-09-16 |
Alza Corporation |
Liposome composition for targeting egfr receptor
|
US8536113B2
(en)
*
|
2006-12-21 |
2013-09-17 |
Janssen Biotech, Inc. |
EGFR binding peptides and uses thereof
|
WO2008079976A2
(en)
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Dimeric high affinity egfr constructs and uses thereof
|
JP2010513321A
(ja)
*
|
2006-12-22 |
2010-04-30 |
ノヴェリクス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
少なくとも一種の上皮細胞増殖因子受容体特異抗体またはその誘導体を用いる糖尿病の治療
|
DK2426143T3
(en)
|
2007-01-05 |
2017-09-11 |
Univ Zuerich |
Process for providing disease-specific binding molecules and targets
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
PT2740744T
(pt)
|
2007-01-09 |
2018-06-06 |
Biogen Ma Inc |
Anticorpos sp35 e suas utilizações
|
AU2008205512B2
(en)
|
2007-01-16 |
2014-06-12 |
Abbvie Inc. |
Methods for treating psoriasis
|
JP5276017B2
(ja)
|
2007-01-25 |
2013-08-28 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Egfr変異体仲介性疾患の治療における抗egfr抗体の使用
|
KR20080074683A
(ko)
*
|
2007-02-09 |
2008-08-13 |
삼성전자주식회사 |
디지털 저작권 관리 방법 및 장치
|
US8114606B2
(en)
|
2007-02-16 |
2012-02-14 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies
|
US8685666B2
(en)
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
WO2008104386A2
(en)
|
2007-02-27 |
2008-09-04 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
JP5726417B2
(ja)
*
|
2007-03-01 |
2015-06-03 |
シムフォゲン・アクティーゼルスカブSymphogen A/S |
組み換え抗上皮成長因子受容体抗体組成物
|
EP2899541A1
(en)
|
2007-03-02 |
2015-07-29 |
Genentech, Inc. |
Predicting response to a HER dimerisation inhbitor based on low HER3 expression
|
AR065687A1
(es)
|
2007-03-13 |
2009-06-24 |
Amgen Inc |
Metodo para determinar la presencia o no de una mutacion k-ras y terapia con anticuerpos anti-egfr
|
CL2008000716A1
(es)
|
2007-03-13 |
2008-09-22 |
Amgen Inc |
Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras y b-raf en un tumor del paciente.
|
CN101688229B
(zh)
|
2007-03-15 |
2013-06-12 |
路德维格癌症研究所 |
包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
JP5456658B2
(ja)
|
2007-03-30 |
2014-04-02 |
メディミューン,エルエルシー |
抗体製剤
|
PA8775101A1
(es)
|
2007-04-02 |
2008-11-19 |
Pfizer |
Anticuerpos anti-ige
|
MX2009012341A
(es)
|
2007-05-14 |
2010-02-17 |
Medimmune Llc |
Metodos para reducir niveles de eosinofilos.
|
PL2171090T3
(pl)
|
2007-06-08 |
2013-09-30 |
Genentech Inc |
Markery ekspresji genów odporności guza na leczenie hamujące HER2
|
EP2158221B1
(en)
|
2007-06-21 |
2018-08-29 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
WO2008154927A1
(en)
*
|
2007-06-21 |
2008-12-24 |
Genmab A/S |
Novel methods for treating egfr-associated tumors
|
CN101896503B
(zh)
|
2007-08-14 |
2018-05-22 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
WO2009025846A2
(en)
|
2007-08-22 |
2009-02-26 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
WO2009032661A1
(en)
|
2007-08-29 |
2009-03-12 |
Sanofi-Aventis |
Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
|
SI2193142T1
(sl)
|
2007-08-30 |
2015-05-29 |
Curedm Group Holdings, Llc |
Sestavek in postopek za uporabo proislet peptidov in analogov le-teh
|
WO2009036209A2
(en)
|
2007-09-14 |
2009-03-19 |
Amgen Inc. |
Homogeneous antibody populations
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
WO2009054917A1
(en)
*
|
2007-10-19 |
2009-04-30 |
Amgen Inc. |
Methods of selecting epidermal growth factor receptor (egfr) binding agents
|
EP2214708A4
(en)
|
2007-10-26 |
2011-01-12 |
Centocor Ortho Biotech Inc |
VECTORS, HOST CELLS, METHODS OF PRODUCTION AND USES
|
AU2008324800B2
(en)
|
2007-11-05 |
2014-03-27 |
Astrazeneca Ab |
Methods of treating scleroderma
|
US9308257B2
(en)
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
EP2238169A1
(en)
|
2007-12-26 |
2010-10-13 |
Biotest AG |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
HUE024903T2
(en)
|
2007-12-26 |
2016-02-29 |
Xencor Inc |
FC variants with modified binding to FCRN
|
CA2710471C
(en)
|
2007-12-26 |
2018-06-05 |
Biotest Ag |
Immunoconjugates targeting cd138 and uses thereof
|
CN101945892B
(zh)
|
2007-12-26 |
2017-11-24 |
生物测试股份公司 |
用于改进对表达cd138的肿瘤细胞的靶向的方法和试剂
|
KR101626416B1
(ko)
|
2007-12-26 |
2016-06-01 |
바이오테스트 아게 |
Cd138 표적 물질 및 이의 용도
|
JP5690593B2
(ja)
|
2007-12-26 |
2015-03-25 |
ヴァクシネックス, インコーポレイテッド |
抗c35抗体併用療法および方法
|
US8454960B2
(en)
*
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
US8557243B2
(en)
*
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8557242B2
(en)
*
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
KR20100107501A
(ko)
|
2008-01-18 |
2010-10-05 |
메디뮨 엘엘씨 |
부위 특이적 접합을 위한 시스테인 조작 항체
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
AU2009209541A1
(en)
*
|
2008-01-30 |
2009-08-06 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
PL2250279T3
(pl)
|
2008-02-08 |
2016-11-30 |
|
Przeciwciała anty-ifnar1 o zmniejszonym powinowactwie do liganda fc
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
MX2010009782A
(es)
*
|
2008-03-07 |
2010-09-30 |
Pharma Mar Sa |
Tratamientos antitumorales mejorados.
|
WO2009117289A2
(en)
|
2008-03-18 |
2009-09-24 |
Abbott Laboratories |
Methods for treating psoriasis
|
WO2009118300A1
(en)
|
2008-03-25 |
2009-10-01 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
EP2274008B1
(en)
|
2008-03-27 |
2014-02-26 |
ZymoGenetics, Inc. |
Compositions and methods for inhibiting pdgfrbeta and vegf-a
|
PE20091827A1
(es)
*
|
2008-04-11 |
2009-11-20 |
Galaxy Biotech Llc |
Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
|
CA2722043A1
(en)
|
2008-04-25 |
2009-10-29 |
Toray Industries, Inc. |
Nucleic acid comprising chimeric gene derived from hepatitis c virus
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
US9029508B2
(en)
|
2008-04-29 |
2015-05-12 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
CN102076865B
(zh)
|
2008-05-02 |
2016-03-16 |
西雅图基因公司 |
用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
|
CA2723219A1
(en)
|
2008-05-09 |
2009-11-12 |
Abbott Gmbh & Co. Kg |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
WO2009148896A2
(en)
|
2008-05-29 |
2009-12-10 |
Nuclea Biotechnologies, LLC |
Anti-phospho-akt antibodies
|
CN102112494A
(zh)
|
2008-06-03 |
2011-06-29 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
EP3002299A1
(en)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
JP5674654B2
(ja)
|
2008-07-08 |
2015-02-25 |
アッヴィ・インコーポレイテッド |
プロスタグランジンe2二重可変ドメイン免疫グロブリンおよびその使用
|
BRPI0915825A2
(pt)
|
2008-07-08 |
2015-11-03 |
Abbott Lab |
proteínas de ligação à prostaglandina e2 usos das mesmas
|
EP2315779A2
(en)
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Compositions comprising antibodies to lingo or fragments thereof
|
KR20110031393A
(ko)
|
2008-07-21 |
2011-03-25 |
더 브리검 앤드 우먼즈 하스피털, 인크. |
합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
|
AU2009281713B9
(en)
|
2008-08-14 |
2014-05-29 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-IL-12/IL-23 antibodies
|
BRPI0916973A2
(pt)
|
2008-08-18 |
2016-07-26 |
Amgen Fremont Inc |
anticorpos para ccr2
|
CA2732856C
(en)
*
|
2008-08-29 |
2018-08-28 |
Symphogen A/S |
Cancer treatment with a combination of two different anti-epidermal growth factor receptor antibodies
|
WO2010027364A1
(en)
|
2008-09-07 |
2010-03-11 |
Glyconex Inc. |
Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
|
RU2536937C2
(ru)
|
2008-10-14 |
2014-12-27 |
Дженентек, Инк. |
Варианты иммуноглобулина и их применения
|
EP3351628B1
(en)
|
2008-10-24 |
2023-07-26 |
The Government of The United States of America as represented by The Secretary, Department of Health and Human Services |
Human ebola virus species and compositions and methods thereof
|
US8642280B2
(en)
|
2008-11-07 |
2014-02-04 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
EP2191842A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
EP2191841A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
EP2191843A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
CA2745271A1
(en)
*
|
2008-12-04 |
2010-06-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
HUE043084T2
(hu)
|
2008-12-19 |
2019-08-28 |
Macrogenics Inc |
Kovalens diatestek és alkalmazásaik
|
EP2382238A1
(en)
|
2008-12-31 |
2011-11-02 |
Biogen Idec MA Inc. |
Anti-lymphotoxin antibodies
|
CN106995495A
(zh)
|
2009-01-12 |
2017-08-01 |
希托马克斯医疗有限责任公司 |
修饰抗体组合物及其制备和使用方法
|
WO2010085510A1
(en)
|
2009-01-20 |
2010-07-29 |
Zadeh Homayoun H |
Antibody mediated osseous regeneration
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP2396035A4
(en)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
|
US8399219B2
(en)
|
2009-02-23 |
2013-03-19 |
Cytomx Therapeutics, Inc. |
Protease activatable interferon alpha proprotein
|
EP2810652A3
(en)
|
2009-03-05 |
2015-03-11 |
AbbVie Inc. |
IL-17 binding proteins
|
EP2405920A1
(en)
|
2009-03-06 |
2012-01-18 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Novel therapy for anxiety
|
AR075896A1
(es)
|
2009-03-20 |
2011-05-04 |
Genentech Inc |
Anticuerpos anti-her (factor de crecimiento epidermico)
|
RU2542394C2
(ru)
|
2009-03-24 |
2015-02-20 |
ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. |
Гуманизированные антитела против light и их применение
|
EP2413962A1
(en)
|
2009-03-30 |
2012-02-08 |
Mount Sinai School of Medicine |
Influenza virus vaccines and uses thereof
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
KR20110138412A
(ko)
|
2009-04-16 |
2011-12-27 |
애보트 바이오테라퓨틱스 코포레이션 |
항-ΤΝF-α 항체 및 그의 용도
|
JP5785941B2
(ja)
|
2009-06-17 |
2015-09-30 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
抗vegf抗体とその使用
|
WO2011005481A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
US20120288495A1
(en)
|
2009-07-22 |
2012-11-15 |
Biothera, Inc. |
Therapeutic compositions and methods
|
WO2011014504A1
(en)
|
2009-07-27 |
2011-02-03 |
Mount Sinai School Of Medicine Of New York University |
Recombinant influenza virus vectors and uses thereof
|
TW201109438A
(en)
*
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US8828406B2
(en)
|
2009-07-30 |
2014-09-09 |
Icahn School Of Medicine At Mount Sinai |
Influenza viruses and uses thereof
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
EA023179B1
(ru)
|
2009-08-13 |
2016-05-31 |
Круселл Холланд Б.В. |
Антитела против респираторного синцитиального вируса (pcb) и способы их применения
|
US8623358B2
(en)
|
2009-08-29 |
2014-01-07 |
Abbvie Inc. |
Therapeutic DLL4 binding proteins
|
EP2473524A4
(en)
|
2009-09-01 |
2013-05-22 |
Abbott Lab |
IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
ES2354922B1
(es)
|
2009-09-02 |
2012-02-07 |
Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron |
Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
US20120244170A1
(en)
|
2009-09-22 |
2012-09-27 |
Rafal Ciosk |
Treating cancer by modulating mex-3
|
UY32914A
(es)
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
Anticuerpos que se usan específicamente al receptor epha2
|
ES2672121T3
(es)
|
2009-10-07 |
2018-06-12 |
Macrogenics, Inc. |
Polipéptidos que contienen región Fc que presentan una función efectora mejorada debido a alteraciones del grado de fucosilación, y métodos para su uso
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
KR20140015139A
(ko)
|
2009-10-15 |
2014-02-06 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
WO2011059762A1
(en)
|
2009-10-28 |
2011-05-19 |
Abbott Biotherapeutics Corp. |
Anti-egfr antibodies and their uses
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
WO2011053779A2
(en)
|
2009-10-30 |
2011-05-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
WO2011056073A2
(en)
|
2009-11-04 |
2011-05-12 |
Erasmus University Medical Center Rotterdam |
Novel compounds for modulating neovascularisation and methods of treatment using these compounds
|
AR078986A1
(es)
|
2009-11-12 |
2011-12-14 |
Genentech Inc |
Un metodo para promover la densidad de espinas dendriticas
|
PT3351558T
(pt)
|
2009-11-13 |
2020-04-09 |
Daiichi Sankyo Europe Gmbh |
Material e métodos para tratamento ou prevenção de doenças associadas a her-3
|
MX2012006406A
(es)
|
2009-12-04 |
2012-07-25 |
Genentech Inc |
Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
|
SG181563A1
(en)
|
2009-12-08 |
2012-07-30 |
Abbott Gmbh & Co Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
EP2513148B1
(en)
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anti-her2 antibodies and their uses
|
CA2781578A1
(en)
|
2010-01-12 |
2011-07-21 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
US20110189178A1
(en)
*
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
CN102933231B
(zh)
|
2010-02-10 |
2015-07-29 |
伊缪诺金公司 |
Cd20抗体及其用途
|
JP5981853B2
(ja)
|
2010-02-18 |
2016-08-31 |
ジェネンテック, インコーポレイテッド |
ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
|
EP2542582A4
(en)
|
2010-03-02 |
2013-12-04 |
Abbvie Inc |
THERAPEUTIC PROTEINS LINKING TO DLL4
|
EP2542692B1
(en)
|
2010-03-04 |
2016-08-24 |
Carpén, Olli |
Method for selecting patients for treatment with an egfr inhibitor
|
US20130004519A1
(en)
|
2010-03-05 |
2013-01-03 |
Ruth Chiquet-Ehrismann |
Smoci, tenascin-c and brain cancers
|
KR20130001272A
(ko)
|
2010-03-17 |
2013-01-03 |
에프. 호프만-라 로슈 아게 |
이미다조피리딘 및 푸린 화합물, 조성물 및 사용 방법
|
RU2012145183A
(ru)
|
2010-03-29 |
2014-05-10 |
Займворкс, Инк. |
Антитела с повышенной или пониженной эффекторной функцией
|
CN102939103A
(zh)
|
2010-03-30 |
2013-02-20 |
西奈山医学院 |
流感病毒疫苗及其应用
|
EP2371369A1
(en)
|
2010-04-01 |
2011-10-05 |
Institut Gustave Roussy (IGR) |
EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
|
AU2011239689A1
(en)
*
|
2010-04-15 |
2012-11-08 |
Amgen Inc. |
Human FGF receptor and beta-Klotho binding proteins
|
ES2684475T3
(es)
|
2010-04-15 |
2018-10-03 |
Abbvie Inc. |
Proteínas que se unen a beta amiloide
|
WO2011130654A1
(en)
|
2010-04-16 |
2011-10-20 |
Genentech, Inc. |
Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
US20130034543A1
(en)
|
2010-04-19 |
2013-02-07 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Modulating xrn1
|
AU2011252883B2
(en)
|
2010-05-14 |
2015-09-10 |
Abbvie Inc. |
IL-1 binding proteins
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011156617A2
(en)
|
2010-06-09 |
2011-12-15 |
Aveo Pharmaceuticals, Inc. |
Anti-egfr antibodies
|
US20130089538A1
(en)
|
2010-06-10 |
2013-04-11 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
EP2585097B1
(en)
|
2010-06-25 |
2018-09-26 |
Aston University |
Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
MX343298B
(es)
|
2010-07-09 |
2016-11-01 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
WO2012016227A2
(en)
|
2010-07-29 |
2012-02-02 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
SG187682A1
(en)
|
2010-08-02 |
2013-03-28 |
Macrogenics Inc |
Covalent diabodies and uses thereof
|
CN103298834A
(zh)
|
2010-08-03 |
2013-09-11 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
EP2601287B1
(en)
|
2010-08-05 |
2015-01-07 |
Amgen Inc. |
Dipeptides to enhance yield and viability from cell cultures
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
US9062101B2
(en)
|
2010-08-14 |
2015-06-23 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
DK3333188T3
(da)
|
2010-08-19 |
2022-03-07 |
Zoetis Belgium S A |
Anti-NGF-antistoffer og deres anvendelse
|
WO2012024659A2
(en)
|
2010-08-20 |
2012-02-23 |
Massachusetts Institute Of Technology |
Antibody-based constructs directed against tyrosine kinase receptors
|
BR112013004581A2
(pt)
|
2010-08-26 |
2017-06-27 |
Abbvie Inc |
imunoglobulinas de domínio variável dual e seus usos
|
MX2013002084A
(es)
|
2010-08-31 |
2013-05-09 |
Genentech Inc |
Biomarcadores y metodos de tratamiento.
|
US20130171159A1
(en)
|
2010-09-10 |
2013-07-04 |
Brian Arthur Hemmings |
Phosphorylated twist1 and metastasis
|
AR082974A1
(es)
|
2010-09-15 |
2013-01-23 |
Hoffmann La Roche |
Derivados de azabenzotiazol, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para tratar enfermedades inflamatorias
|
DE19177059T1
(de)
|
2010-10-01 |
2021-10-07 |
Modernatx, Inc. |
N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
|
TWI545134B
(zh)
|
2010-10-22 |
2016-08-11 |
西雅圖遺傳學公司 |
以奧裡斯他汀(AURISTATIN)為主之抗體藥物結合物及PI3K-AKT mTOR路徑抑制劑間的協同功效
|
JP5828902B2
(ja)
|
2010-10-29 |
2015-12-09 |
イミュノジェン, インコーポレイテッド |
非拮抗性egfr結合分子およびその免疫複合体
|
BR112013010544A2
(pt)
|
2010-10-29 |
2016-08-02 |
Immunogen Inc |
moléculas de ligação ao egfr e imunoconjugados das mesmas
|
EP2637692A4
(en)
|
2010-11-12 |
2014-09-10 |
Scott & White Healthcare |
ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
|
US20140093506A1
(en)
|
2010-11-15 |
2014-04-03 |
Marc Buehler |
Anti-fungal-agents
|
EP2640384A1
(en)
|
2010-11-18 |
2013-09-25 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
|
BR112013011520A2
(pt)
|
2010-11-19 |
2019-09-24 |
Hoffmann La Roche |
pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
KR20130133247A
(ko)
|
2010-12-21 |
2013-12-06 |
애브비 인코포레이티드 |
Il-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
AU2012211014A1
(en)
|
2011-01-24 |
2013-05-02 |
National Research Council Of Canada |
Antibodies selective for cells presenting EGFR at high density
|
EP3763740A1
(en)
|
2011-01-26 |
2021-01-13 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
EP3235508B1
(en)
|
2011-03-16 |
2020-12-30 |
Sanofi |
Compositions comprising a dual v region antibody-like protein
|
DE12722942T1
(de)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
EP2694552B1
(en)
|
2011-04-07 |
2017-10-11 |
Amgen Inc. |
Novel egfr binding proteins
|
CA2833748C
(en)
|
2011-04-20 |
2019-07-16 |
Amgen Inc. |
Autoinjector apparatus
|
DK2699264T3
(en)
|
2011-04-20 |
2018-06-25 |
Medimmune Llc |
ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
|
US9133493B2
(en)
|
2011-04-21 |
2015-09-15 |
Amgen Inc. |
Method for culturing mammalian cells to improve recombinant protein production
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
UA111612C2
(uk)
|
2011-05-21 |
2016-05-25 |
Макродженікс, Інк. |
Домени, які зв'язуються з деімунізованою сироваткою, і їхнє застосування для збільшення часу напівжиття в сироватці
|
CN106432506A
(zh)
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
EP2717911A1
(en)
|
2011-06-06 |
2014-04-16 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
RU2014100111A
(ru)
|
2011-06-10 |
2015-07-20 |
МЕДИММЬЮН, ЭлЭлСи |
МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
WO2012175537A1
(en)
|
2011-06-20 |
2012-12-27 |
Traslational Cancer Drugs Pharma, S.L. |
Method for predicting the clinical response to chemotherapy in a subject with cancer
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
LT2726600T
(lt)
|
2011-07-01 |
2017-05-25 |
Amgen Inc. |
Žinduolių ląstelių kultūra
|
WO2019071023A1
(en)
|
2017-10-04 |
2019-04-11 |
Yale University |
COMPOSITIONS AND METHODS FOR MAKING POLYPEPTIDES CONTAINING SELENOCYSTEINE
|
WO2013009868A1
(en)
|
2011-07-11 |
2013-01-17 |
Yale University |
Compositions and methods for making selenocysteine containing polypeptides
|
EP2734236A4
(en)
|
2011-07-13 |
2015-04-15 |
Abbvie Inc |
METHOD AND COMPOSITIONS FOR TREATING ASTHMA WITH ANTI-IL-13 ANTIBODIES
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
RU2014105624A
(ru)
|
2011-08-12 |
2015-09-20 |
Ф. Хоффманн-Ля Рош Аг |
Соединения индазола, способ их применения и фармацевтическая композиция
|
JP6120848B2
(ja)
|
2011-08-15 |
2017-04-26 |
メディミューン,エルエルシー |
抗b7−h4抗体およびその使用
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
JP2015527869A
(ja)
|
2011-08-26 |
2015-09-24 |
メリマック ファーマシューティカルズ インコーポレーティッド |
タンデムFc二重特異性抗体
|
CA2840637A1
(en)
|
2011-09-02 |
2013-03-07 |
Amgen Inc. |
Pharmaceutical product and method of analysing light exposure of a pharmaceutical product
|
US9447192B2
(en)
|
2011-09-09 |
2016-09-20 |
Medimmune Limited |
Anti-Siglec-15 antibodies and uses thereof
|
MX351251B
(es)
|
2011-09-09 |
2017-10-06 |
Amgen Inc |
Uso del estado del virus del papiloma humano en establecer el uso de un agente que enlaza el receptor del factor de crecimiento anti-epidermal en el tratamiento de cáncer.
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CN103827115A
(zh)
|
2011-09-20 |
2014-05-28 |
弗·哈夫曼-拉罗切有限公司 |
咪唑并吡啶化合物、组合物和使用方法
|
CN104185476A
(zh)
|
2011-09-20 |
2014-12-03 |
西奈山医学院 |
流感病毒疫苗及其应用
|
JP6113737B2
(ja)
|
2011-10-03 |
2017-04-12 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
|
DK2766392T3
(da)
|
2011-10-10 |
2019-10-07 |
Xencor Inc |
Fremgangsmåde til oprensning af antistoffer
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
WO2013056069A1
(en)
|
2011-10-13 |
2013-04-18 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
IN2014CN03936A
(el)
|
2011-10-24 |
2015-09-04 |
Abbvie Inc |
|
WO2013063095A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Immunobinders directed against sclerostin
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
US9220774B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Methods of treating cancer by administering anti-GPR49 antibodies
|
EP2773665A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
EP2773373B1
(en)
|
2011-11-01 |
2018-08-22 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
WO2013068431A1
(en)
|
2011-11-08 |
2013-05-16 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
EP2776838A1
(en)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Early diagnostic of neurodegenerative diseases
|
US20140323549A1
(en)
|
2011-11-08 |
2014-10-30 |
Quark Pharmaceuticals, Inc. |
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
US20140322216A1
(en)
|
2011-11-08 |
2014-10-30 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
RU2014114015A
(ru)
|
2011-11-08 |
2015-12-20 |
Пфайзер Инк. |
Способы лечения воспалительных расстройств с использованием антител против m-csf
|
SG11201402365RA
(en)
|
2011-11-16 |
2014-06-27 |
Amgen Inc |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
RU2014121820A
(ru)
|
2011-11-21 |
2015-12-27 |
Иммьюноджен, Инк. |
Способ лечения опухолей, устойчивых к анти-egfr терапиям, с помощью конъюгата антитела egfr с цитотоксическим средством
|
CN106987620A
(zh)
|
2011-11-30 |
2017-07-28 |
霍夫曼-拉罗奇有限公司 |
癌症中的erbb3突变
|
CA2858133A1
(en)
|
2011-12-08 |
2013-06-13 |
Biotest Ag |
Uses of immunoconjugates targeting cd138
|
CA2855840C
(en)
|
2011-12-14 |
2023-08-29 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
EP2791175A2
(en)
|
2011-12-14 |
2014-10-22 |
Abbvie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
AR089231A1
(es)
|
2011-12-15 |
2014-08-06 |
Amgen Inc |
Metodo de floculacion
|
MX2014007233A
(es)
|
2011-12-16 |
2015-02-04 |
Moderna Therapeutics Inc |
Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
|
CN103172741B
(zh)
*
|
2011-12-20 |
2018-04-27 |
智翔(上海)医药科技有限公司 |
全人源抗egfr抗体
|
US11147852B2
(en)
|
2011-12-23 |
2021-10-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
AR089529A1
(es)
|
2011-12-30 |
2014-08-27 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
|
US20140363448A1
(en)
|
2012-01-02 |
2014-12-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
WO2013107290A1
(en)
|
2012-01-20 |
2013-07-25 |
The Government of the Hong Kong Special Administrative Region of the People's Republic of China |
A novel paramyxovirus and uses thereof
|
RU2644337C2
(ru)
|
2012-01-27 |
2018-02-08 |
Эббви Дойчланд Гмбх Унд Ко. Кг |
Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов
|
MX363819B
(es)
*
|
2012-02-08 |
2019-04-03 |
Igm Biosciences Inc |
Uniones a cdim y sus usos.
|
EP2812702B1
(en)
|
2012-02-10 |
2019-04-17 |
Seattle Genetics, Inc. |
Diagnosis and management of CD30-expressing cancers
|
EP2814842B1
(en)
|
2012-02-15 |
2018-08-22 |
Novo Nordisk A/S |
Antibodies that bind peptidoglycan recognition protein 1
|
PL2814844T3
(pl)
|
2012-02-15 |
2017-12-29 |
Novo Nordisk A/S |
Przeciwciała wiążące i blokujące receptor aktywujący wykazujący ekspresję na komórkach szpikowych -1 (trem-1)
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
EP2831112A1
(en)
|
2012-03-29 |
2015-02-04 |
Friedrich Miescher Institute for Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
EP2834259A4
(en)
|
2012-04-02 |
2016-08-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
WO2013155447A1
(en)
|
2012-04-13 |
2013-10-17 |
Children's Medical Center Corporation |
Tiki inhibitors
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
WO2013166043A1
(en)
|
2012-05-02 |
2013-11-07 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
CN104470541A
(zh)
|
2012-05-14 |
2015-03-25 |
比奥根艾迪克Ma公司 |
用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
|
US9512223B2
(en)
|
2012-05-15 |
2016-12-06 |
Morphotek, Inc. |
Methods for treatment of gastric cancer
|
JP6441792B2
(ja)
*
|
2012-05-17 |
2018-12-19 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Egfrに結合する抗原結合蛋白質
|
WO2013174432A1
(en)
|
2012-05-24 |
2013-11-28 |
Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) |
Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
ES2718478T3
(es)
|
2012-06-08 |
2019-07-02 |
Sutro Biopharma Inc |
Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
|
EP2866831A1
(en)
|
2012-06-29 |
2015-05-06 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
EP2870242A1
(en)
|
2012-07-05 |
2015-05-13 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
US20150224190A1
(en)
|
2012-07-06 |
2015-08-13 |
Mohamed Bentires-Alj |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
CN104583230A
(zh)
|
2012-07-13 |
2015-04-29 |
宾夕法尼亚大学董事会 |
通过共同引入双特异性抗体增强car t细胞的活性
|
PL2882440T3
(pl)
|
2012-08-07 |
2019-07-31 |
Novartis Ag |
Kombinacje farmaceutyczne zawierające inhibitor b-raf, inhibitor egfr i opcjonalnie inhibitor pi3k-alfa
|
AU2013308494B2
(en)
|
2012-08-31 |
2018-03-01 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
CA2883272A1
(en)
|
2012-09-02 |
2014-03-06 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
NO2760138T3
(el)
|
2012-10-01 |
2018-08-04 |
|
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
US9598489B2
(en)
|
2012-10-05 |
2017-03-21 |
The Trustees Of The Univeristy Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
CA2885340C
(en)
|
2012-10-12 |
2016-11-08 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
US10253107B2
(en)
|
2012-10-26 |
2019-04-09 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
CA2889488A1
(en)
|
2012-11-01 |
2014-05-08 |
Abbvie Inc. |
Stable dual variable domain immunoglobulin protein formulations
|
PE20151179A1
(es)
|
2012-11-01 |
2015-09-12 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
CA2892529C
(en)
|
2012-11-26 |
2023-04-25 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
CN108641002A
(zh)
|
2012-12-18 |
2018-10-12 |
西奈山伊坎医学院 |
流感病毒疫苗及其用途
|
EP2934576A1
(en)
|
2012-12-19 |
2015-10-28 |
The Johns Hopkins University |
Anti-human b7-h4 antibodies and their uses
|
BR112015014621A2
(pt)
|
2012-12-21 |
2017-10-03 |
Amplimmune Inc |
Anticorpos anti-h7cr
|
EP3620473A1
(en)
|
2013-01-14 |
2020-03-11 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
WO2014109858A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
AU2014207549B2
(en)
|
2013-01-15 |
2018-12-06 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
WO2014129895A1
(en)
|
2013-02-19 |
2014-08-28 |
Stichting Vu-Vumc |
Means and method for increasing the sensitivity of cancers for radiotherapy
|
WO2014128235A1
(en)
|
2013-02-22 |
2014-08-28 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer and preventing drug resistance
|
EA201591652A1
(ru)
|
2013-03-06 |
2016-02-29 |
Мерримак Фармасьютикалз, Инк. |
ТАНДЕМНЫЕ БИСПЕЦИФИЧЕСКИЕ Fc-АНТИТЕЛА ПРОТИВ c-MET
|
RU2015137610A
(ru)
|
2013-03-06 |
2017-04-10 |
Дженентек, Инк. |
Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
|
CA2905010A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
KR102241868B1
(ko)
|
2013-03-13 |
2021-04-20 |
사노피 |
항-cd38 항체 및 카르필조밉을 포함하는 조성물
|
AU2014230735B2
(en)
|
2013-03-13 |
2018-03-15 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2014139326A1
(en)
|
2013-03-13 |
2014-09-18 |
Genentech, Inc. |
Pyrazolo compounds and uses thereof
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
TWI771890B
(zh)
|
2013-03-14 |
2022-07-21 |
美商安美基公司 |
用於增加重組蛋白質之甘露糖含量之方法
|
US9194873B2
(en)
|
2013-03-14 |
2015-11-24 |
Abbott Laboratories |
HCV antigen-antibody combination assay and methods and compositions for use therein
|
EP2969099B2
(en)
|
2013-03-14 |
2021-12-22 |
Amgen Inc. |
Removal of leaked affinity purification ligand
|
US20140272969A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbott Molecular Inc. |
Cell preparations and cell supports and their use in theranosis
|
US20160185853A1
(en)
|
2013-03-14 |
2016-06-30 |
Parkash Gill |
Cancer treatment using antibodies that bind cell surface grp78
|
US9790478B2
(en)
|
2013-03-14 |
2017-10-17 |
Abbott Laboratories |
HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
|
CN105378099B
(zh)
|
2013-03-14 |
2021-05-11 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
US9908930B2
(en)
|
2013-03-14 |
2018-03-06 |
Icahn School Of Medicine At Mount Sinai |
Antibodies against influenza virus hemagglutinin and uses thereof
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
KR20150127216A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
암의 치료 및 암 약물 내성의 예방 방법
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
US10167341B2
(en)
|
2013-03-15 |
2019-01-01 |
Memorial Sloan Kettering Cancer Center |
High affinity anti-GD2 antibodies
|
BR112015023797A2
(pt)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
|
JP6768501B2
(ja)
|
2013-03-15 |
2020-10-14 |
アムゲン・インコーポレーテッド |
薬物カセット、自動注入機、および自動注入機システム
|
JP6449229B2
(ja)
|
2013-03-15 |
2019-01-09 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Fc変異体
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
CN105451767B
(zh)
|
2013-03-15 |
2019-10-18 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2970488A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Biotechnology Ltd |
Anti-cd25 antibodies and their uses
|
CA2904527A1
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Biotechnology Ltd. |
Anti-cd25 antibodies and their uses
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
BR112015023203A8
(pt)
|
2013-03-15 |
2018-01-23 |
Constellation Pharmaceuticals Inc |
métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
|
CA2906927C
(en)
|
2013-03-15 |
2021-07-13 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
EP2968760B1
(en)
|
2013-03-15 |
2024-01-03 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
BR112015025549A2
(pt)
*
|
2013-04-07 |
2017-10-10 |
Bioex Therapeutics Inc |
anticorpo contra o receptor do fator de crescimento epidérmico
|
BR112015025347A2
(pt)
|
2013-04-09 |
2017-07-18 |
Boston Biomedical Inc |
2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer
|
EP4032540A1
(en)
|
2013-04-19 |
2022-07-27 |
Cytune Pharma |
Cytokine derived treatment with reduced vascular leak syndrome
|
TWI679019B
(zh)
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
抗il-4/抗il-13之雙特異性抗體調配物
|
CA2911514A1
(en)
|
2013-05-06 |
2014-11-13 |
Scholar Rock, Inc. |
Compositions and methods for growth factor modulation
|
CN103290018B
(zh)
*
|
2013-05-07 |
2015-07-29 |
南方医科大学 |
一种与人表皮生长因子受体iii型突变体特异性结合的核酸适配子及其应用
|
JP6682426B2
(ja)
|
2013-05-24 |
2020-04-15 |
メディミューン,エルエルシー |
抗b7−h5抗体およびその使用
|
US9481901B2
(en)
|
2013-05-30 |
2016-11-01 |
Amgen Inc. |
Methods for increasing mannose content of recombinant proteins
|
US10100123B2
(en)
|
2013-06-06 |
2018-10-16 |
Pierre Fabre Medicament |
Anti-C10orf54 antibodies and uses thereof
|
US10183988B2
(en)
|
2013-06-07 |
2019-01-22 |
Duke University |
Anti-Complement factor H antibodies
|
US20160151486A1
(en)
|
2013-06-13 |
2016-06-02 |
Fast Foward Pharmaceuticals B.V. |
CD40 Signalling Inhibitor and a Further Compound, Wherein the Further Compound is a Bile Acid, a Bile Acid Derivative, an TGR5-Receptor Agonist, an FXR Agonist or a Combination Thereof, for the Treatment of Chronic Inflammation, and the Prevention of Gastrointestinal Cancer or Fibrosis
|
US9499628B2
(en)
|
2013-06-14 |
2016-11-22 |
Children's Hospital Medical Center |
Method of boosting the immune response in neonates
|
EP3016980B1
(en)
|
2013-07-05 |
2020-05-06 |
Formation Biologics Inc. |
Egfr antibody conjugates
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
ES2761587T3
(es)
|
2013-08-07 |
2020-05-20 |
Friedrich Miescher Institute For Biomedical Res |
Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
US9505767B2
(en)
|
2013-09-05 |
2016-11-29 |
Genentech, Inc. |
Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
|
MX2016002870A
(es)
|
2013-09-05 |
2017-02-23 |
Amgen Inc |
Moleculas que contienen fc que presentan perfiles de glicoforma predecibles, consistentes y reproducibles.
|
ES2959451T3
(es)
|
2013-09-11 |
2024-02-26 |
Eagle Biologics Inc |
Formulaciones proteicas líquidas que contienen organofosfatos
|
CN105764924A
(zh)
|
2013-09-12 |
2016-07-13 |
哈洛齐梅公司 |
修饰的抗表皮生长因子受体抗体及其使用方法
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
AR097894A1
(es)
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
Inhibidores terapéuticos de cdk8 o uso de los mismos
|
CA2926218A1
(en)
|
2013-10-03 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
KR20160070136A
(ko)
|
2013-10-18 |
2016-06-17 |
제넨테크, 인크. |
항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
CA3120508A1
(en)
|
2013-10-28 |
2015-05-07 |
Dots Technology Corp. |
Allergen detection
|
US20150118251A1
(en)
|
2013-10-31 |
2015-04-30 |
Sanofi |
Specific anti-cd38 antibodies for treating human cancers
|
WO2015066357A1
(en)
|
2013-10-31 |
2015-05-07 |
Amgen Inc. |
Use of monensin to regulate glycosylation of recombinant proteins
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
JP2017500307A
(ja)
|
2013-12-12 |
2017-01-05 |
ノバルティス アーゲー |
がんの処置のためのトラメチニブ、パニツムマブおよびダブラフェニブの組合せ
|
WO2015088346A1
(en)
|
2013-12-13 |
2015-06-18 |
Rijksuniversiteit Groningen |
Antibodies against staphylococcus aureus and uses thereof.
|
CN106102774A
(zh)
|
2013-12-17 |
2016-11-09 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
|
BR112016013896A2
(pt)
|
2013-12-17 |
2017-10-10 |
Genentech Inc |
métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2
|
WO2015097536A2
(en)
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutical Nv |
Anti-vista antibodies and fragments
|
EP2893939A1
(en)
|
2014-01-10 |
2015-07-15 |
Netris Pharma |
Anti-netrin-1 antibody
|
MX2016009084A
(es)
|
2014-01-13 |
2016-10-13 |
Amgen Inc |
Regulacion del metabolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteinas recombinantes.
|
WO2015116315A1
(en)
|
2014-01-29 |
2015-08-06 |
Amgen Inc. |
Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
EP2915569A1
(en)
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
MX2016012285A
(es)
|
2014-03-24 |
2017-01-23 |
Genentech Inc |
Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
|
ME03666B
(me)
|
2014-03-28 |
2020-10-20 |
Xencor Inc |
Bispecifična antitela koja se vezuju za cd38 i cd3
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
HUE046767T2
(hu)
|
2014-03-31 |
2020-03-30 |
Hoffmann La Roche |
Anti-OX40 antitestek és alkalmazási eljárások
|
JP6614582B2
(ja)
|
2014-04-04 |
2019-12-04 |
バイオノミクス インコーポレイテッド |
Lgr5に結合するヒト化抗体
|
US20170044257A1
(en)
|
2014-04-25 |
2017-02-16 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
EP3143404B1
(en)
|
2014-05-16 |
2018-08-29 |
Amgen Inc. |
Assay for detecting th1 and th2 cell populations
|
CN106413750B
(zh)
|
2014-05-16 |
2022-04-29 |
免疫医疗有限责任公司 |
具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
|
AU2015266958A1
(en)
|
2014-05-28 |
2016-12-08 |
Agenus Inc. |
Anti-GITR antibodies and methods of use thereof
|
KR102391259B1
(ko)
|
2014-06-04 |
2022-04-26 |
암젠 인크 |
포유류 세포 배양물을 회수하는 방법
|
ES2779974T3
(es)
|
2014-06-13 |
2020-08-21 |
Tenboron Oy |
Conjugados que comprenden un anticuerpo anti-egfr1
|
EP3154579A1
(en)
|
2014-06-13 |
2017-04-19 |
Friedrich Miescher Institute for Biomedical Research |
New treatment against influenza virus
|
EP3157535A1
(en)
|
2014-06-23 |
2017-04-26 |
Friedrich Miescher Institute for Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
WO2016001830A1
(en)
|
2014-07-01 |
2016-01-07 |
Friedrich Miescher Institute For Biomedical Research |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
RS65136B1
(sr)
|
2014-07-17 |
2024-02-29 |
Novo Nordisk As |
Mutageza usmerena na lokaciju trem-1 antitela za smanjenje viskoziteta
|
WO2018140026A1
(en)
|
2017-01-27 |
2018-08-02 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
KR20240011258A
(ko)
|
2014-09-02 |
2024-01-25 |
이뮤노젠 아이엔씨 |
항체 약물 컨쥬게이트 조성물의 제형화 방법
|
CN107074823B
(zh)
|
2014-09-05 |
2021-05-04 |
基因泰克公司 |
治疗性化合物及其用途
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
CN107073125A
(zh)
|
2014-09-19 |
2017-08-18 |
基因泰克公司 |
Cbp/ep300和bet抑制剂用于治疗癌症的用途
|
EP3197557A1
(en)
|
2014-09-24 |
2017-08-02 |
Friedrich Miescher Institute for Biomedical Research |
Lats and breast cancer
|
KR102497368B1
(ko)
|
2014-10-01 |
2023-02-10 |
이글 바이올로직스 인코포레이티드 |
점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
|
JP6783230B2
(ja)
|
2014-10-10 |
2020-11-11 |
ジェネンテック, インコーポレイテッド |
ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
|
JP2017536347A
(ja)
|
2014-10-17 |
2017-12-07 |
ノバルティス アーゲー |
セリチニブとegfr阻害剤の組合せ
|
CA2959841A1
(en)
|
2014-10-23 |
2016-04-28 |
Innate Pharma |
Treatment of cancers using anti-nkg2a agents
|
JP2017537893A
(ja)
|
2014-10-31 |
2017-12-21 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
抗cs1抗体および抗体薬結合体
|
CN107106609A
(zh)
|
2014-10-31 |
2017-08-29 |
宾夕法尼亚大学董事会 |
刺激和扩展t细胞的组合物和方法
|
EP3215168B1
(en)
|
2014-10-31 |
2023-08-02 |
The Trustees of the University of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
BR112017009151A2
(pt)
|
2014-11-03 |
2018-03-06 |
Genentech, Inc. |
ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
|
MX2017005751A
(es)
|
2014-11-03 |
2018-04-10 |
Genentech Inc |
Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
|
SG11201703376QA
(en)
|
2014-11-06 |
2017-05-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
WO2016077375A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
PT3218005T
(pt)
|
2014-11-12 |
2023-04-11 |
Seagen Inc |
Compostos que interagem com glicano e métodos de uso
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
CA2968372A1
(en)
|
2014-11-19 |
2016-05-26 |
Amgen Inc. |
Quantitation of glycan moiety in recombinant glycoproteins
|
KR20170084327A
(ko)
|
2014-11-26 |
2017-07-19 |
젠코어 인코포레이티드 |
Cd3 및 cd38에 결합하는 이형이량체 항체
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
EP3223845B1
(en)
|
2014-11-26 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd20
|
WO2016086200A1
(en)
|
2014-11-27 |
2016-06-02 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
EA202091598A3
(ru)
|
2014-12-01 |
2021-01-29 |
Эмджен Инк. |
Процесс контроля уровня содержания гликанов в составе
|
RU2020123953A
(ru)
|
2014-12-09 |
2020-09-18 |
Эббви Инк. |
Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и конъюгаты антитело-лекарственное средство, включающие их
|
US20170182179A1
(en)
|
2014-12-09 |
2017-06-29 |
Abbvie Inc. |
Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors
|
EP3229836B1
(en)
|
2014-12-09 |
2019-11-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Human monoclonal antibodies against axl
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
DK3229838T3
(da)
|
2014-12-11 |
2020-10-19 |
Pf Medicament |
Anti-C10orf54-antistoffer og anvendelser deraf
|
WO2016097420A1
(en)
|
2014-12-19 |
2016-06-23 |
Universite De Nantes |
Anti il-34 antibodies
|
ES2862701T3
(es)
|
2014-12-22 |
2021-10-07 |
Univ Rockefeller |
Anticuerpos agonistas anti-MERTK y usos de los mismos
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
EP3237639A2
(en)
|
2014-12-23 |
2017-11-01 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
EP3240908A2
(en)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
JP2018504400A
(ja)
|
2015-01-08 |
2018-02-15 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Lingo‐1拮抗薬及び脱髄障害の治療のための使用
|
EP3242875B1
(en)
|
2015-01-09 |
2022-02-23 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
CN107406429B
(zh)
|
2015-01-09 |
2021-07-06 |
基因泰克公司 |
哒嗪酮衍生物及其在治疗癌症中的用途
|
CN107406414B
(zh)
|
2015-01-09 |
2022-04-19 |
基因泰克公司 |
作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物
|
SG10201906471PA
(en)
|
2015-01-14 |
2019-09-27 |
Brigham & Womens Hospital Inc |
Treatment of cancer with anti-lap monoclonal antibodies
|
WO2016118937A1
(en)
|
2015-01-23 |
2016-07-28 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccination regimens
|
JP6709792B2
(ja)
|
2015-01-29 |
2020-06-17 |
ジェネンテック, インコーポレイテッド |
治療用化合物およびその使用
|
CN107438593B
(zh)
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
US10828353B2
(en)
|
2015-01-31 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for T cell delivery of therapeutic molecules
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
HRP20230046T1
(hr)
|
2015-03-03 |
2023-03-03 |
Kymab Limited |
Protutijela, upotreba i postupci
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
EP3265483B1
(en)
|
2015-03-06 |
2019-12-11 |
CSL Behring Lengnau AG |
Modified von willebrand factor having improved half-life
|
CA2979976A1
(en)
|
2015-03-17 |
2016-09-22 |
Memorial Sloan Kettering Cancer Center |
Anti-muc16 antibodies and uses thereof
|
JP6955445B2
(ja)
|
2015-04-07 |
2021-10-27 |
ジェネンテック, インコーポレイテッド |
アゴニスト性の活性を有する抗原結合複合体及びその使用方法
|
AU2016256911B2
(en)
|
2015-05-07 |
2022-03-31 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
LT3294770T
(lt)
|
2015-05-12 |
2020-12-28 |
F. Hoffmann-La Roche Ag |
Vėžio gydymo ir diagnostikos būdai
|
ES2962885T3
(es)
|
2015-05-15 |
2024-03-21 |
Massachusetts Gen Hospital |
Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral
|
MX2017014736A
(es)
|
2015-05-29 |
2018-03-23 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para cancer.
|
SI3303394T1
(sl)
|
2015-05-29 |
2020-10-30 |
Agenus Inc. |
Protitelesa proti-CTLA-4 in postopki njihove uporabe
|
SI3303395T1
(sl)
|
2015-05-29 |
2020-03-31 |
Abbvie Inc. |
Protitelesa proti CD40 in njihove uporabe
|
TW201717935A
(zh)
|
2015-06-03 |
2017-06-01 |
波士頓生醫公司 |
用於治療癌症的組成物和方法
|
US20160355597A1
(en)
|
2015-06-08 |
2016-12-08 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
WO2016200835A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
CN107771076A
(zh)
|
2015-06-17 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
EP3313882B1
(en)
|
2015-06-24 |
2020-03-11 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
CN108026110B
(zh)
|
2015-08-26 |
2022-02-08 |
国家公共部门基金会卡洛斯三世国家癌症研究中心(F.S.P.Cnio) |
作为蛋白激酶抑制剂的稠合三环化合物
|
US11713358B2
(en)
|
2015-08-28 |
2023-08-01 |
Amunix Pharmaceuticals, Inc. |
Chimeric polypeptide assembly and methods of making and using the same
|
KR102434314B1
(ko)
|
2015-09-01 |
2022-08-19 |
아게누스 인코포레이티드 |
항-pd-1 항체 및 이를 이용하는 방법
|
AU2016325610B2
(en)
|
2015-09-25 |
2019-10-10 |
Genentech, Inc. |
Anti-TIGIT antibodies and methods of use
|
WO2017072669A1
(en)
|
2015-10-28 |
2017-05-04 |
Friedrich Miescher Institute For Biomedical Research |
Tenascin-w and biliary tract cancers
|
AR106543A1
(es)
|
2015-11-02 |
2018-01-24 |
Netris Pharma |
Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
|
JP2019500011A
(ja)
|
2015-11-03 |
2019-01-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
|
SG11201803213XA
(en)
|
2015-11-12 |
2018-05-30 |
Siamab Therapeutics Inc |
Glycan-interacting compounds and methods of use
|
WO2017091745A1
(en)
|
2015-11-25 |
2017-06-01 |
Immunogen, Inc. |
Pharmaceutical formulations and methods of use thereof
|
CA3006610A1
(en)
|
2015-11-30 |
2017-06-08 |
Abbvie Inc. |
Anti-hulrrc15 antibody drug conjugates and methods for their use
|
EP3383909B1
(en)
|
2015-11-30 |
2020-06-17 |
AbbVie Inc. |
Anti-human lrrc15 antibody drug conjugates and methods for their use
|
MX2018006613A
(es)
|
2015-12-02 |
2019-01-30 |
Stcube & Co Inc |
Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
|
WO2017096017A1
(en)
|
2015-12-02 |
2017-06-08 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
JP7058219B2
(ja)
|
2015-12-07 |
2022-04-21 |
ゼンコア インコーポレイテッド |
Cd3及びpsmaに結合するヘテロ二量体抗体
|
EP3978500B1
(en)
|
2015-12-16 |
2023-11-22 |
Genentech, Inc. |
Process for the preparation of tricyclic pi3k inhibitor compounds
|
EP3184544A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein v inhibitors for use as coagulants
|
EA037015B1
(ru)
|
2015-12-31 |
2021-01-27 |
Прогастрин Э Кансер С.А Р.Л. |
Применение и способ для профилактики или лечения рака яичников с использованием композиции, содержащей прогастринсвязывающее антитело
|
US20190011449A1
(en)
|
2015-12-31 |
2019-01-10 |
Progastrine Et Cancers S.À R.L. |
Compositions and methods for detecting and treating gastric cancer
|
JP7018885B2
(ja)
|
2015-12-31 |
2022-02-14 |
プロガストリン、エ、カンセル、エス、アー エル、エル |
食道癌の検出および治療のための組成物および方法
|
CN114705858A
(zh)
|
2015-12-31 |
2022-07-05 |
Syncerus有限责任公司 |
用于评估癌症发生的风险的组合物和方法
|
PL3400246T3
(pl)
|
2016-01-08 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
|
MX2018009800A
(es)
|
2016-02-12 |
2018-11-09 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
CN116239693A
(zh)
|
2016-03-14 |
2023-06-09 |
奥斯陆大学 |
具有改变的FcRn结合的工程化免疫球蛋白
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
RS61412B1
(sr)
|
2016-03-17 |
2021-03-31 |
Tillotts Pharma Ag |
Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
|
EP3430044A1
(en)
|
2016-03-17 |
2019-01-23 |
Numab Innovation AG |
Anti-tnf alpha -antibodies and functional fragments thereof
|
US10787508B2
(en)
|
2016-03-17 |
2020-09-29 |
Numab Innovation Ag |
Anti-TNFα-antibodies and functional fragments thereof
|
IL261098B1
(en)
|
2016-03-17 |
2024-05-01 |
Numab Therapeutics AG |
Antibodies against TNF-ALPHA and their functional fragments
|
EP3219726B1
(en)
|
2016-03-17 |
2020-12-02 |
Tillotts Pharma AG |
Anti-tnf alpha-antibodies and functional fragments thereof
|
JP2019509322A
(ja)
|
2016-03-22 |
2019-04-04 |
バイオノミクス リミテッド |
抗lgr5モノクローナル抗体の投与
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
EA201892190A1
(ru)
|
2016-03-29 |
2019-04-30 |
Янссен Байотек, Инк. |
Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
EP3865511A1
(en)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3 antibodies and methods of use
|
MX2018012493A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para controlar y tratar el cáncer.
|
ES2850428T3
(es)
|
2016-04-15 |
2021-08-30 |
Hoffmann La Roche |
Procedimientos de monitorización y tratamiento del cáncer
|
WO2017180581A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
TW201808336A
(zh)
|
2016-05-11 |
2018-03-16 |
賽諾菲公司 |
用抗muc1類美登素免疫綴合物抗體治療腫瘤的治療方案
|
RS60663B1
(sr)
|
2016-05-17 |
2020-09-30 |
Abbvie Biotherapeutics Inc |
Konjugati anti-cmet antitelo-lek i metodi za njihovu primenu
|
WO2017205536A2
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
US11649291B2
(en)
|
2016-05-24 |
2023-05-16 |
Insmed Incorporated |
Antibodies and methods of making same
|
CN109476663B
(zh)
|
2016-05-24 |
2021-11-09 |
基因泰克公司 |
用于治疗癌症的吡唑并吡啶衍生物
|
RS62726B1
(sr)
|
2016-05-27 |
2022-01-31 |
Abbvie Biotherapeutics Inc |
Anti-cd40 antitela i njihove upotrebe
|
US10875921B2
(en)
|
2016-05-27 |
2020-12-29 |
Abbvie Biotherapeutics Inc. |
Anti-4-1BB antibodies and their uses
|
CN109476751B
(zh)
|
2016-05-27 |
2024-04-19 |
艾吉纳斯公司 |
抗tim-3抗体及其使用方法
|
AU2017272337C1
(en)
|
2016-06-03 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
|
CN116284404A
(zh)
|
2016-06-08 |
2023-06-23 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
JP2019527037A
(ja)
|
2016-06-08 |
2019-09-26 |
ジェネンテック, インコーポレイテッド |
がんのための診断及び治療方法
|
CA3027209C
(en)
|
2016-06-13 |
2022-08-16 |
I-Mab |
Anti-pd-l1 antibodies and uses thereof
|
RU2022104399A
(ru)
|
2016-06-14 |
2022-05-05 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
WO2017218698A1
(en)
|
2016-06-15 |
2017-12-21 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
CN109641041A
(zh)
|
2016-06-15 |
2019-04-16 |
西奈山伊坎医学院 |
流感病毒血细胞凝集素蛋白及其用途
|
US10316088B2
(en)
|
2016-06-28 |
2019-06-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
CA3030099A1
(en)
|
2016-07-08 |
2018-01-11 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
MX2019002946A
(es)
|
2016-09-14 |
2019-09-26 |
Abbvie Biotherapeutics Inc |
Anticuerpos anti-pd-1 y sus usos.
|
CA3036509C
(en)
|
2016-09-19 |
2022-10-25 |
I-Mab |
Anti-gm-csf antibodies and uses thereof
|
EP3515478B1
(en)
|
2016-09-21 |
2024-02-28 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
EP4360714A2
(en)
|
2016-09-21 |
2024-05-01 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
CA3037961A1
(en)
|
2016-09-30 |
2018-04-05 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-il23 specific antibody
|
US20180106800A1
(en)
|
2016-10-03 |
2018-04-19 |
Abbott Laboratories |
Methods of assessing uch-l1 status in patient samples
|
EP3523451A1
(en)
|
2016-10-06 |
2019-08-14 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2018069289A1
(en)
|
2016-10-11 |
2018-04-19 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
WO2018071500A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
KR102562519B1
(ko)
|
2016-10-14 |
2023-08-02 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
抗mic抗体及び使用方法
|
CA3041843A1
(en)
|
2016-11-02 |
2018-05-11 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and parp inhibitors
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
WO2018083538A1
(en)
|
2016-11-07 |
2018-05-11 |
Neuracle Scienc3 Co., Ltd. |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
MA46861A
(fr)
|
2016-11-16 |
2019-09-25 |
Janssen Biotech Inc |
Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
JP7106563B2
(ja)
|
2016-11-29 |
2022-07-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
ナフトフラン誘導体、その調製、および使用方法
|
HRP20231579T1
(hr)
|
2016-12-07 |
2024-03-15 |
Agenus Inc. |
Anti-ctla-4 antitijela i postupci njihove upotrebe
|
EP3551225A1
(en)
|
2016-12-07 |
2019-10-16 |
Agenus Inc. |
Antibodies and methods of use thereof
|
UA125041C2
(uk)
|
2016-12-15 |
2021-12-29 |
Еббві Байотерапьютікс Інк. |
Анти-ox40 антитіла і їх застосування
|
EA039433B1
(ru)
|
2017-01-05 |
2022-01-27 |
Нетрис Фарма |
Комбинированное лечение лекарственными средствами, интерферирующими с нетрином-1, и лекарственными средствами, ингибиторами контрольных точек иммуного ответа
|
WO2018133837A1
(en)
|
2017-01-20 |
2018-07-26 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anti-pd-1 antibodies and uses thereof
|
US10584169B2
(en)
|
2017-01-24 |
2020-03-10 |
I-Mab Biopharma Us Limited |
Anti-CD73 antibodies and uses thereof
|
MX2019008989A
(es)
|
2017-01-30 |
2019-10-09 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa.
|
MX2019009377A
(es)
|
2017-02-07 |
2019-12-11 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
|
CA3052670A1
(en)
|
2017-03-01 |
2018-09-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
AU2018226824A1
(en)
|
2017-03-03 |
2019-09-19 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
MA47775A
(fr)
|
2017-03-14 |
2020-01-22 |
Amgen Inc |
Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
|
TWI808963B
(zh)
|
2017-03-22 |
2023-07-21 |
法商賽諾菲公司 |
使用人類化抗cxcr5抗體治療狼瘡
|
CA3052513A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
KR102616819B1
(ko)
|
2017-03-30 |
2023-12-21 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
폐암을 치료하기 위한 조성물 및 방법
|
KR102351556B1
(ko)
|
2017-03-30 |
2022-01-14 |
프로가스트린 에 캔서스 에스.에이 알.엘. |
프로가스트린 결합 분자를 사용하는 전립선암의 검출 및 치료를 위한 조성물 및 방법
|
CA3058652A1
(en)
|
2017-04-07 |
2018-10-11 |
Icahn School Of Medicine At Mount Sinai |
Anti-influenza b virus neuraminidase antibodies and uses thereof
|
MX2019012187A
(es)
|
2017-04-13 |
2019-11-25 |
Hoffmann La Roche |
Un inmunoconjugado de interleuquina-2, un agonista de cd40 y opcionalmente un antagonista de union al eje pd-1 para uso en metodos para tratar cancer.
|
CA3059366A1
(en)
|
2017-04-13 |
2018-10-18 |
Agenus Inc. |
Anti-cd137 antibodies and methods of use thereof
|
EP3610268A1
(en)
|
2017-04-15 |
2020-02-19 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
AU2018255938A1
(en)
|
2017-04-21 |
2019-10-31 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
US20230140818A1
(en)
|
2017-04-27 |
2023-05-04 |
The University Of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
JP7080899B2
(ja)
|
2017-04-28 |
2022-06-06 |
アボット・ラボラトリーズ |
同じヒト対象に由来する少なくとも2つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
|
DK3618863T3
(da)
|
2017-05-01 |
2023-08-21 |
Agenus Inc |
Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
US10646569B2
(en)
|
2017-05-16 |
2020-05-12 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
WO2018213424A1
(en)
|
2017-05-17 |
2018-11-22 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
CA3078725A1
(en)
|
2017-05-25 |
2018-11-29 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
AU2018275236A1
(en)
|
2017-05-30 |
2019-10-31 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I
|
US20200131266A1
(en)
|
2017-05-31 |
2020-04-30 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
CA3065301A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
WO2018226671A1
(en)
|
2017-06-06 |
2018-12-13 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
MA49517A
(fr)
|
2017-06-30 |
2020-05-06 |
Xencor Inc |
Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
|
AU2018300189A1
(en)
|
2017-07-14 |
2020-01-30 |
Pfizer, Inc. |
Antibodies to MAdCAM
|
KR20200093518A
(ko)
|
2017-07-21 |
2020-08-05 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
WO2020159504A1
(en)
|
2019-01-30 |
2020-08-06 |
Nomocan Pharmaceuticals Llc |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
US20210032364A1
(en)
|
2017-07-27 |
2021-02-04 |
Nomocan Pharmaceuticals Llc |
Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
|
CA3070297A1
(en)
|
2017-08-11 |
2019-02-14 |
Genentech, Inc. |
Anti-cd8 antibodies and uses thereof
|
KR20200045520A
(ko)
|
2017-09-07 |
2020-05-04 |
오거스타 유니버시티 리서치 인스티튜트, 인크. |
프로그래밍된 세포사 단백질 1에 대한 항체
|
TWI827550B
(zh)
|
2017-09-08 |
2024-01-01 |
美商建南德克公司 |
癌症之診斷及治療方法
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
US11123330B2
(en)
|
2017-09-28 |
2021-09-21 |
The Governing Council Of The University Of Toronto |
Methods and compositions for inhibiting mutant EGFR signaling
|
EP3694552A1
(en)
|
2017-10-10 |
2020-08-19 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
US20190160089A1
(en)
|
2017-10-31 |
2019-05-30 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and cytarabine
|
MX2020004512A
(es)
|
2017-10-31 |
2020-08-13 |
|
Anticuerpos anti apolipoproteina c-iii (anti-apoc3) y metodos de uso de los mismos.
|
CN111213059B
(zh)
|
2017-11-06 |
2024-01-09 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
MX2020005066A
(es)
|
2017-11-16 |
2020-08-20 |
Amgen Inc |
Autoinyector con deteccion de detencion y punto final.
|
MX2020005473A
(es)
|
2017-11-27 |
2020-08-27 |
Purdue Pharma Lp |
Anticuerpos humanizados que se dirigen al factor tisular humano.
|
WO2019110662A1
(en)
|
2017-12-05 |
2019-06-13 |
Progastrine Et Cancers S.À R.L. |
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
|
AU2018378084A1
(en)
|
2017-12-09 |
2020-05-14 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
|
BR112019028254A2
(pt)
|
2017-12-09 |
2020-07-14 |
Abbott Laboratories |
métodos para ajudar no diagnóstico e avaliação de um paciente que sofreu uma lesão ortopédica e que sofreu ou pode ter sofrido uma lesão na cabeça, tal como uma lesão cerebral traumática (lct) leve, usando a proteína ácida fibrilar glial (gfap) e/ou a hidrolase carbóxi-terminal da ubiquitina l1 (uch-l1)
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
TW201940881A
(zh)
|
2018-01-26 |
2019-10-16 |
瑞士商Ecs前胃泌激素公司 |
在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
|
CA3092108A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
EP3759492A1
(en)
|
2018-02-27 |
2021-01-06 |
ECS-Progastrin SA |
Progastrin as a biomarker for immunotherapy
|
WO2019169229A1
(en)
|
2018-03-01 |
2019-09-06 |
Nextcure, Inc. |
Klrg1 binding compositions and methods of use thereof
|
MA54132A
(fr)
|
2018-03-05 |
2022-04-27 |
Janssen Biotech Inc |
Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
|
CN111819197A
(zh)
|
2018-03-12 |
2020-10-23 |
硕腾服务有限责任公司 |
抗ngf抗体及其方法
|
BR112020019559A2
(pt)
|
2018-03-26 |
2021-01-12 |
Amgen Inc. |
Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
|
TWI790370B
(zh)
|
2018-04-02 |
2023-01-21 |
美商必治妥美雅史谷比公司 |
抗trem-1抗體及其用途
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
EP3773739A1
(en)
|
2018-04-12 |
2021-02-17 |
MediaPharma S.r.l. |
Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
|
WO2019204665A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
CN112437777A
(zh)
|
2018-04-18 |
2021-03-02 |
Xencor股份有限公司 |
包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
|
EP3784274A1
(en)
|
2018-04-27 |
2021-03-03 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
AU2019265888A1
(en)
|
2018-05-10 |
2020-11-26 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
MA52590A
(fr)
|
2018-05-11 |
2021-03-17 |
Janssen Biotech Inc |
Méthodes de traitement de la dépression à l'aide d'anticorps il-23
|
WO2019222130A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and flt3 inhibitors
|
US20210363590A1
(en)
|
2018-05-21 |
2021-11-25 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
JP2021524449A
(ja)
|
2018-05-23 |
2021-09-13 |
アーデーセー セラピューティクス ソシエテ アノニム |
分子アジュバント
|
CA3104291A1
(en)
|
2018-06-21 |
2019-12-26 |
Yumanity Therapeutics, Inc. |
Compositions and methods for the treatment and prevention of neurological disorders
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
WO2020003210A1
(en)
|
2018-06-29 |
2020-01-02 |
Kangwon National University University-Industry Cooperation Foundation |
Anti-l1cam antibodies and uses thereof
|
US10976561B2
(en)
|
2018-06-29 |
2021-04-13 |
Viavi Solutions Inc. |
Optical devices with azimuthal modulator layer
|
JP2021530697A
(ja)
|
2018-07-18 |
2021-11-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体で治療した後の持続応答予測因子
|
US20200171146A1
(en)
|
2018-07-18 |
2020-06-04 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
WO2020016459A1
(en)
|
2018-07-20 |
2020-01-23 |
Pierre Fabre Medicament |
Receptor for vista
|
WO2020028909A1
(en)
|
2018-08-03 |
2020-02-06 |
Brown University |
Oral formulations with increased uptake
|
EP3847154A1
(en)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
CA3111401A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
KR20210062634A
(ko)
|
2018-09-21 |
2021-05-31 |
제넨테크, 인크. |
3중-음성 유방암에 대한 진단 방법
|
US10961307B2
(en)
|
2018-09-24 |
2021-03-30 |
Janssen Biotech, Inc. |
Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody
|
CA3115096A1
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
JP2022504287A
(ja)
|
2018-10-03 |
2022-01-13 |
スターテン・バイオテクノロジー・ベー・フェー |
ヒト及びカニクイザルapoc3に特異的な抗体、並びにその使用の方法
|
GB201816553D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
GB201816554D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
EP3863722A2
(en)
|
2018-10-10 |
2021-08-18 |
Tilos Theapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
EP3863672A4
(en)
|
2018-10-11 |
2022-06-29 |
The Scripps Research Institute |
Antibody compounds with reactive arginine and related antibody drug conjugates
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
AU2019383017A1
(en)
|
2018-11-20 |
2021-06-03 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
|
JP2022507718A
(ja)
|
2018-11-20 |
2022-01-18 |
コーネル ユニバーシティー |
放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
US20220026445A1
(en)
|
2018-12-07 |
2022-01-27 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
US20220064325A1
(en)
|
2018-12-17 |
2022-03-03 |
Alligator Bioscience Ab |
Novel polypeptides
|
US20220073635A1
(en)
|
2018-12-17 |
2022-03-10 |
Alligator Bioscience Ab |
Novel polypeptides
|
US20200197517A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
|
US20220081438A1
(en)
|
2018-12-19 |
2022-03-17 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
EP3898615A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
|
EP3902829A2
(en)
|
2018-12-26 |
2021-11-03 |
Innate Pharma |
Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
|
CA3125316A1
(en)
|
2018-12-28 |
2020-07-02 |
Kyowa Kirin Co., Ltd. |
Bispecific antibody binding to tfr
|
CN113574066A
(zh)
|
2019-01-15 |
2021-10-29 |
詹森生物科技公司 |
用于治疗幼年特发性关节炎的抗tnf抗体组合物和方法
|
EA202192038A1
(ru)
|
2019-01-23 |
2021-10-05 |
Янссен Байотек, Инк. |
Композиции антител к фно для применения в способах лечения псориатического артрита
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
US11639388B2
(en)
|
2019-02-22 |
2023-05-02 |
Wuhan Yzy Biopharma Co., Ltd. |
CD3 antigen binding fragment and application thereof
|
MA55080A
(fr)
|
2019-02-26 |
2022-01-05 |
Inspirna Inc |
Anticorps anti-mertk à affinité élevée et utilisations associées
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
CN113677994A
(zh)
|
2019-02-27 |
2021-11-19 |
外延轴治疗股份有限公司 |
用于评估t细胞功能和预测对疗法的应答的方法和药剂
|
US11472890B2
(en)
|
2019-03-01 |
2022-10-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
JP2022524860A
(ja)
|
2019-03-14 |
2022-05-10 |
ヤンセン バイオテツク,インコーポレーテツド |
抗tnf抗体組成物を産生するための方法
|
EP3938384A4
(en)
|
2019-03-14 |
2022-12-28 |
Janssen Biotech, Inc. |
METHODS OF MANUFACTURING FOR PRODUCING ANTI-IL12/IL23 ANTIBODY COMPOSITIONS
|
US20220144934A1
(en)
|
2019-03-14 |
2022-05-12 |
Janssen Biotech, Inc. |
Methods for Producing Anti-TNF Antibody Compositions
|
US20220153830A1
(en)
|
2019-03-14 |
2022-05-19 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-TNF Antibody Compositions
|
AU2020241428A1
(en)
|
2019-03-15 |
2021-08-12 |
Cartesian Therapeutics, Inc. |
Anti-BCMA chimeric antigen receptors
|
MA55383A
(fr)
|
2019-03-18 |
2022-01-26 |
Janssen Biotech Inc |
Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
|
CN113661180A
(zh)
|
2019-03-27 |
2021-11-16 |
宾夕法尼亚大学董事会 |
Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
|
US20220169706A1
(en)
|
2019-03-28 |
2022-06-02 |
Danisco Us Inc |
Engineered antibodies
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
TW202108616A
(zh)
|
2019-05-03 |
2021-03-01 |
美商建南德克公司 |
用抗pd-l1抗體治療癌症之方法
|
CN113874073A
(zh)
|
2019-05-23 |
2021-12-31 |
詹森生物科技公司 |
用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
|
CA3142665A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
WO2020245677A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
WO2020252043A1
(en)
|
2019-06-10 |
2020-12-17 |
Sutro Biopharma, Inc. |
5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF
|
WO2020257235A1
(en)
|
2019-06-17 |
2020-12-24 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
JP2022545741A
(ja)
|
2019-08-30 |
2022-10-28 |
アジェナス インコーポレイテッド |
抗cd96抗体およびその使用方法
|
US20220348650A1
(en)
|
2019-09-03 |
2022-11-03 |
Bio-Thera Solutions, Ltd. |
Anti-tigit immunosuppressant and application thereof
|
CR20220095A
(es)
|
2019-09-04 |
2022-06-06 |
Genentech Inc |
Agentes de unión a cd8 y usos de los mismos
|
EP4041767A1
(en)
|
2019-09-26 |
2022-08-17 |
StCube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
AU2020355251A1
(en)
|
2019-09-26 |
2022-04-21 |
Amgen Inc. |
Methods of producing antibody compositions
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
US20220356248A1
(en)
|
2019-10-09 |
2022-11-10 |
Stcube & Co |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
JP2023511472A
(ja)
|
2019-10-29 |
2023-03-20 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二官能性化合物
|
CA3155922A1
(en)
|
2019-11-06 |
2021-05-14 |
Huang Huang |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
CN114728905A
(zh)
|
2019-11-13 |
2022-07-08 |
基因泰克公司 |
治疗性化合物及使用方法
|
EP3825330A1
(en)
|
2019-11-19 |
2021-05-26 |
International-Drug-Development-Biotech |
Anti-cd117 antibodies and methods of use thereof
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
CA3164995A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
EP4087657A1
(en)
|
2020-01-08 |
2022-11-16 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
EP4114860A1
(en)
|
2020-03-06 |
2023-01-11 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
TW202140044A
(zh)
|
2020-03-06 |
2021-11-01 |
日商第一三共股份有限公司 |
含有新穎環狀雙核苷酸衍生物之抗體藥物共軛物
|
WO2021183207A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
EP4130035A1
(en)
|
2020-03-31 |
2023-02-08 |
Bio-Thera Solutions, Ltd. |
Antibody and fusion protein for treating coronaviruses and use thereof
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
EP4136459A1
(en)
|
2020-04-13 |
2023-02-22 |
Abbott Laboratories |
Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample
|
IL297545A
(en)
|
2020-04-26 |
2022-12-01 |
Biocytogen Pharmaceuticals Beijing Co Ltd |
Modified immunoglobulins
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
EP3915641A1
(en)
|
2020-05-27 |
2021-12-01 |
International-Drug-Development-Biotech |
Anti-cd5 antibodies and methods of use thereof
|
EP3915576A1
(en)
|
2020-05-28 |
2021-12-01 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Chimeric antigen receptors specific for p95her2 and uses thereof
|
EP4161653A1
(en)
|
2020-06-03 |
2023-04-12 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
WO2021247892A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists
|
WO2022002874A1
(en)
|
2020-06-30 |
2022-01-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
|
WO2022002873A1
(en)
|
2020-06-30 |
2022-01-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
|
EP3939999A1
(en)
|
2020-07-14 |
2022-01-19 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
EP4185322A2
(en)
|
2020-07-24 |
2023-05-31 |
Amgen Inc. |
Immunogens derived from sars-cov2 spike protein
|
JP2023536602A
(ja)
|
2020-08-03 |
2023-08-28 |
ジェネンテック, インコーポレイテッド |
リンパ腫のための診断及び治療方法
|
WO2022031804A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
TW202214698A
(zh)
|
2020-08-07 |
2022-04-16 |
大陸商百奧泰生物製藥股份有限公司 |
抗pd-l1抗體及其應用
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
US20230372484A1
(en)
|
2020-09-14 |
2023-11-23 |
Vor Biopharma Inc. |
Chimeric antigen receptors for treatment of cancer
|
AU2021347232A1
(en)
|
2020-09-23 |
2023-04-27 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
EP4225443A1
(en)
|
2020-10-05 |
2023-08-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
EP4229080A1
(en)
|
2020-10-15 |
2023-08-23 |
Amgen Inc. |
Relative unpaired glycans in antibody production methods
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
US20240067728A1
(en)
|
2020-11-06 |
2024-02-29 |
Bio-Thera Solutions, Ltd. |
Bispecific antibody and use thereof
|
WO2022103983A2
(en)
|
2020-11-11 |
2022-05-19 |
Sutro Biopharma, Inc. |
Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
|
CN114478770A
(zh)
|
2020-11-12 |
2022-05-13 |
迈威(上海)生物科技股份有限公司 |
抗体及其制备方法
|
WO2022104697A1
(en)
*
|
2020-11-20 |
2022-05-27 |
Bliss Biopharmaceutical (Hangzhou) Co., Ltd. |
Modified egfr antibody with reduced affinity
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
US20220170948A1
(en)
|
2020-12-01 |
2022-06-02 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
CA3209579A1
(en)
|
2021-01-27 |
2022-08-04 |
Innovent Biologics (Suzhou) Co., Ltd. |
Single-domain antibody against cd16a and use thereof
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體-免疫賦活化劑共軛物之新穎製造方法
|
AU2022221124A1
(en)
|
2021-02-12 |
2023-08-03 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
JP2024512324A
(ja)
|
2021-03-05 |
2024-03-19 |
ジーオー セラピューティクス,インコーポレイテッド |
抗グリコcd44抗体およびその使用
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
AU2022233792A1
(en)
|
2021-03-12 |
2023-10-26 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
BR112023018400A2
(pt)
|
2021-03-12 |
2023-12-12 |
Janssen Biotech Inc |
Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23
|
JPWO2022191313A1
(el)
|
2021-03-12 |
2022-09-15 |
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
IL308183A
(en)
|
2021-05-04 |
2024-01-01 |
Regeneron Pharma |
Multispecific FGF21 receptor agonists and their uses
|
BR112023024169A2
(pt)
|
2021-05-18 |
2024-02-06 |
Abbott Lab |
Métodos para avaliar lesão cerebral em um indivíduo pediátrico
|
KR20240026948A
(ko)
|
2021-05-25 |
2024-02-29 |
에라스카, 아이엔씨. |
황 함유 헤테로방향족 트리사이클릭 kras 억제제
|
AU2022289365A1
(en)
|
2021-06-07 |
2023-12-14 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
EP4356129A1
(en)
|
2021-06-14 |
2024-04-24 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
AU2022293999A1
(en)
|
2021-06-14 |
2023-11-30 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
KR20240034218A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물을 생산하기 위한 제조 방법
|
CN117916260A
(zh)
|
2021-07-09 |
2024-04-19 |
詹森生物科技公司 |
用于制备抗il12/il23抗体组合物的制造方法
|
KR20240032991A
(ko)
|
2021-07-09 |
2024-03-12 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물의 생성을 위한 제조 방법
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
WO2023010118A1
(en)
|
2021-07-29 |
2023-02-02 |
Vor Biopharma Inc. |
Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
|
CA3228178A1
(en)
|
2021-08-05 |
2023-02-09 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
TW202321261A
(zh)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
選擇性kras抑制劑
|
IL310862A
(en)
|
2021-08-16 |
2024-04-01 |
Hemogenyx Pharmaceuticals Llc |
Antibodies against FLT3, chimeric antigen receptors, chimeric antigen receptor T cells and methods of use
|
IL310861A
(en)
|
2021-08-17 |
2024-04-01 |
Hemogenyx Pharmaceuticals Llc |
Bispecific antibodies against FLT3 and CD3 and methods of use
|
WO2023034777A1
(en)
|
2021-08-31 |
2023-03-09 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
AU2022339819A1
(en)
|
2021-09-03 |
2024-04-11 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
WO2023034569A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
WO2023051663A1
(zh)
|
2021-09-30 |
2023-04-06 |
百奥泰生物制药股份有限公司 |
抗b7-h3抗体及其应用
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
AU2022361382A1
(en)
|
2021-10-05 |
2024-03-28 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
CA3236779A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
WO2023079058A1
(en)
|
2021-11-05 |
2023-05-11 |
Yokogawa Insilico Biotechnology Gmbh |
Cell culture with reduced production of lactate
|
WO2023084488A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
US20230159633A1
(en)
|
2021-11-23 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
US20230203062A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023164487A1
(en)
|
2022-02-22 |
2023-08-31 |
Brown University |
Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
|
EP4245772A1
(en)
|
2022-03-18 |
2023-09-20 |
Netris Pharma |
Anti-netrin-1 antibody to treat liver inflammation
|
EP4249509A1
(en)
|
2022-03-22 |
2023-09-27 |
Netris Pharma |
Anti-netrin-1 antibody against arthritis-associated pain
|
EP4253418A1
(en)
|
2022-03-29 |
2023-10-04 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof
|
WO2023186968A1
(en)
|
2022-03-29 |
2023-10-05 |
Netris Pharma |
Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
|
US20230312703A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis with IL-23 Specific Antibody
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024006272A1
(en)
|
2022-06-27 |
2024-01-04 |
Sutro Biopharma, Inc. |
β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024015229A1
(en)
|
2022-07-15 |
2024-01-18 |
Sutro Biopharma, Inc. |
Protease/enzyme cleavable linker-payloads and protein conjugates
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|